Compare Teradyne, Inc. (TER) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs TG Therapeutics Inc — how do they compare? Teradyne, Inc. trades at $403.5 (market cap $59.34B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Teradyne, Inc. is far larger — about 7.8× TG Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TER | TGTX | |
|---|---|---|
Market Cap | $59.34B | $7.64B |
Sector | Technology | Health |
52-Week High | $483.84 | $59.06 |
52-Week Low | $109.30 | $26.94 |
Enterprise Value | $59.09B | $7.84B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) is trading at $402.65, up 10.28% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows robust fundamentals with record revenue of $1.3 billion in Q2, net income margin of 25.77%, and consistent earnings beats. Technical indicators suggest bullish momentum with the current price near resistance at $400, while analyst consensus remains strongly positive with a $481.63 price target.
Outlook remains positive driven by AI-led semiconductor test demand and robotics growth, though elevated valuation multiples (P/E 52.14) and market volatility present risks. The company's strong guidance and institutional support suggest continued upside potential, but investors should monitor competitive pressures in the semiconductor equipment sector.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
